Edmond DE Rothschild Holding S.A. Grows Stock Position in Abbott Laboratories $ABT

Edmond DE Rothschild Holding S.A. boosted its holdings in Abbott Laboratories (NYSE:ABT) by 31.3% during the second quarter, HoldingsChannel reports. The fund owned 107,798 shares of the healthcare product maker’s stock after buying an additional 25,667 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Abbott Laboratories were worth $14,662,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Aviso Financial Inc. grew its holdings in shares of Abbott Laboratories by 7.5% during the 2nd quarter. Aviso Financial Inc. now owns 35,476 shares of the healthcare product maker’s stock worth $4,825,000 after purchasing an additional 2,470 shares during the period. Quadcap Wealth Management LLC lifted its position in Abbott Laboratories by 3.1% in the second quarter. Quadcap Wealth Management LLC now owns 8,414 shares of the healthcare product maker’s stock valued at $1,144,000 after buying an additional 251 shares during the last quarter. CreativeOne Wealth LLC boosted its stake in Abbott Laboratories by 82.4% during the second quarter. CreativeOne Wealth LLC now owns 26,911 shares of the healthcare product maker’s stock worth $3,660,000 after buying an additional 12,155 shares during the period. Horizon Kinetics Asset Management LLC increased its position in shares of Abbott Laboratories by 4.2% during the second quarter. Horizon Kinetics Asset Management LLC now owns 10,459 shares of the healthcare product maker’s stock valued at $1,423,000 after acquiring an additional 418 shares during the last quarter. Finally, Foster Dykema Cabot & Partners LLC raised its stake in shares of Abbott Laboratories by 15.0% in the 2nd quarter. Foster Dykema Cabot & Partners LLC now owns 6,955 shares of the healthcare product maker’s stock valued at $946,000 after acquiring an additional 906 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Abbott Laboratories in a research note on Thursday, November 20th. Wells Fargo & Company boosted their price objective on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Barclays raised their target price on Abbott Laboratories from $159.00 to $162.00 and gave the company an “overweight” rating in a report on Friday, October 17th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $147.00 price target on shares of Abbott Laboratories in a research note on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Trading Down 0.5%

Shares of NYSE:ABT opened at $127.44 on Tuesday. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company’s 50 day moving average is $129.87 and its two-hundred day moving average is $131.14. The company has a market cap of $221.61 billion, a PE ratio of 15.97, a P/E/G ratio of 2.36 and a beta of 0.68. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.30. The business had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th were issued a $0.59 dividend. The ex-dividend date was Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.9%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.